Computational Biology Analysis of COVID-19 Receptor-Binding Domains: A Target Site for Indocyanine Green Through Antimicrobial Photodynamic Therapy
Journal of Lasers in Medical Sciences,
Vol. 11 No. 4 (2020),
3 Mehr 2020
,
Page 433-441
Abstract
Introduction: The receptor-binding domain (RBD) in SARS-CoV-2 binds strongly to angiotensin-converting enzyme 2 (ACE2) receptors and causes coronavirus disease 2019 (COVID-19). Antimicrobial photodynamic therapy (aPDT) is a well-established treatment option for the treatment of several viral infections. This in silico study was conducted to target the RBD of SARS-CoV-2 as a target site for aPDT.
Methods: SARS-CoV-2-RBD was selected as a novel target for indocyanine green (ICG) as a photosensitizer during aPDT to exploit its molecular modeling, hierarchical nature of protein structure, and physico-chemical properties using several bioinformatic tools. The binding mode of the RBD to ICG was assessed via protein-ligand docking.
Results: The results of a computational biology analysis revealed that SARS-CoV-2-RBD has 223 amino acids with a molecular weight of 25098.40 Da. RBD is most similar to 6W41 with an E-value of 4e-167, an identity of 100%, and a query cover of 100%. The aliphatic index of the RBD protein sequences was 71.61, suggesting that the protein is stable in a broad spectrum of temperatures. The predicted structure of RBD showed that it is a protein with a positive charge and a random coil structure (69.51%). Four ligands were modeled in this entry, including one N-acetyl-D-glucosamine (NAG), one glycerol (GOL), and two sulfate ions (SO4), to which ICG desires to bind in the molecular docking analysis.
Conclusion: Molecular modeling and simulation analysis showed that SARS-CoV-2-RBD could be a substrate for binding to ICG during aPDT to control the spread of COVID-19.
- Antimicrobial photodynamic therapy
- Bioinformatics tools
- Indocyanine green
- In silico
- SARS-CoV-2
How to Cite
References
Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951. doi: 10.1016/j.ijantimicag.2020.105951.
Singhal T. A review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281-286. doi: 10.1007/s12098-020-03263-6.
Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011-1033. doi: 10.3390/v4061011.
He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773-81. doi: 10.1016/j.bbrc.2004.09.106.
Chen J, Miao L, Li JM, Li YY, Zhu QY, Zhou CL, et al. Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization. World J Gastroenterol. 2005;11(39):6159-64. doi: 10.3748/wjg.v11.i39.6159.
Yin R, Dai T, Avci P, Jorge AE, de Melo WC, Vecchio D, et al. Light based anti-infectives: ultraviolet C irradiation, photodynamic therapy, blue light, and beyond. Curr Opin Pharmacol. 2013;13(5):731-62. doi: 10.1016/j.coph.2013.08.009.
Kharkwal GB, Sharma SK, Huang YY, Dai T, Hamblin MR. Photodynamic therapy for infections: clinical applications. Lasers Surg Med. 2011;43(7):755-67. doi: 10.1002/lsm.21080.
Chang TW, Fiumara N, Weinstein L. Genital herpes: Treatment with methylene blue and light exposure. Int J Dermatol. 1975;14(1):69-71. doi: 10.1111/j.1365-4362.1975.tb00084.x.
Roome AP, Tinkler AE, Hilton AL, Montefiore DG, Waller D. Neutral red with photoinactivation in the treatment of herpes genitalis. Br J Vener Dis. 1975;51(2):130-133. doi: 10.1136/sti.51.2.130.
Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: Immediate and long-term results. Laryngoscope. 1998;108(7):962-967. doi: 10.1097/00005537-199807000-00002.
Abramson AL, Shikowitz MJ, Mullooly VM, Steinberg BM, Amella CA, Rothstein HR. Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. Arch Otolaryngol Head Neck Surg. 1992;118(1):25-29. doi: 10.1001/archotol.1992.01880010029011.
Mohr H, Lambrecht B, Selz A. Photodynamic virus inactivation of blood components. Immunol Invest. 1995;24(1-2):73-85. doi: 10.3109/08820139509062763.
Zhou C, Sun B, Wang F, Dai Z, Han Z, Han J, et al. Coblation plus photodynamic therapy (PDT) for the treatment of juvenile onset laryngeal papillomatosis: case reports. World J Surg Oncol. 2014;12:275. doi: 10.1186/1477-7819-12-275.
Wiehe A, O'Brien JM, Senge MO. Trends and targets in antiviral phototherapy. Photochem Photobiol Sci. 2019;18(11):2565-2612. doi: 10.1039/C9PP00211A.
Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci. 2004;3(5):436-50. doi: 10.1039/b311900a.
Costa L, Faustino MAF, Neves MGP, Cunha A, Almeida A. Photodynamic inactivation of mammalian viruses and bacteriophages. Viruses. 2012;4(7):1034-1074. doi: 10.3390/v4071034.
Baptista MS, Cadet J, Di Mascio P, Ghogare AA, Greer A, Hamblin MR, et al. Type I and type II photosensitized oxidation reactions: Guidelines and mechanistic pathways. Photochem Photobiol. 2017;93(4):912-919. doi: 10.1111/php.12716.
Girotti AW. Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and cytoprotective mechanisms. J Photochem Photobiol B. 2001;63(1-3):103-113. doi: 10.1016/S1011-1344(01)00207-X.
Pourhajibagher M, Bahador A. Evaluation of the crystal structure of a fimbrillin (FimA) from Porphyromonas gingivalis as a therapeutic target for photo-activated disinfection with toluidine blue O. Photodiagnosis Photodyn Ther. 2017;17:98-102. doi: 10.1016/j.pdpdt.2016.11.007.
Pourhajibagher M, Bahador A. Outer membrane protein 100 of Aggregatibacter actinomycetemcomitans act as a biopharmaceutical target for photodynamic therapy: An in silico analysis. Photodiagnosis Photodyn Ther. 2016;16:154-160. doi: 10.1016/j.pdpdt.2016.09.011.
Pourhajibagher M, Bahador A. Designing and in silico analysis of PorB protein from Chlamydia Trachomatis for developing a vaccine candidate. Drug Res (Stuttg). 2016;66(9):479-483. doi: 10.1055/s-0042-110319.
Pramanik K, Ghosh PK, Ray S, Sarkar A, Mitra S, Maiti TK. An in silico structural, functional and phylogenetic analysis with three dimensional protein modeling of alkaline phosphatase enzyme of Pseudomonas aeruginosa. J Genet Eng Biotechnol. 2017;15(2):527-537. doi: 10.1016/j.jgeb.2017.05.003.
Jin C, Yu B, Zhang J, Wu H, Zhou X, Yao H, et al. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for the COVID-19 outbreak. [Preprint]. 2020. Available from: https://doi.org/10.21203/rs.3.rs-17718/v1.
Asnaashari M, Eghbal MJ, Sahba Yaghmayi A, Shokri M, Azari-Marhabi S. Comparison of antibacterial effects of photodynamic therapy, modified triple antibiotic paste and calcium hydroxide on root canals infected with Enterococcus faecalis: an in vitro study. J Lasers Med Sci. 2019;10(Suppl 1):S23-S29. doi: 10.15171/jlms.2019.S5.
Hakimiha N, Khoei F, Bahador A, Fekrazad R. The susceptibility of Streptococcus mutans to antibacterial photodynamic therapy: a comparison of two different photosensitizers and light sources. J Appl Oral Sci. 2014;22(2):80-84. doi: 10.1590/1678-775720130038.
Pérez-Laguna V, Pérez-Artiaga L, Lampaya-Pérez V, García-Luque I, Ballesta S, Nonell S, et al. Bactericidal effect of photodynamic therapy, alone or in combination with mupirocin or linezolid, on
Staphylococcus aureus. Front Microbiol. 2017;8:1002. doi: 10.3389/fmicb.2017.01002.
Hashimoto MC, Prates RA, Kato IT, Núñez SC, Courrol LC, Ribeiro MS. Antimicrobial photodynamic therapy on drug-resistant Pseudomonas aeruginosa-induced infection. An in vivo study. Photochem Photobiol. 2012;88(3):590-95. doi: 10.1111/j.1751-1097.2012.01137.x.
Namvar MA, Vahedi M, Abdolsamadi HR, Mirzaei A, Mohammadi Y, Azizi Jalilian F. Effect of photodynamic therapy by 810 and 940 nm diode laser on Herpes Simplex Virus 1: An in vitro study. Photodiagnosis Photodyn Ther. 2019;25:87-91. doi: 10.1016/j.pdpdt.2018.11.011.
Geralde MC, Leite IS, Inada NM, Salina AC, Medeiros AI, Kuebler WM, et al. Pneumonia treatment by photodynamic therapy with extracorporeal illumination - an experimental model. Physiol Rep. 2017;5(5):13190. doi: 10.14814/phy2.13190.
Urbanska K, Romanowska-Dixon B, Matuszak Z, Oszajca J, Nowak-Sliwinska P, Stochel G. Indocyanine green as a prospective sensitizer for photodynamic therapy of melanomas. Acta Biochim Pol. 2002;49(2):387-391.
Crescenzi E, Varriale L, Iovino M, Chiaviello A, Veneziani BM, Palumbo G. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol Cancer Ther. 2004;3(5):537-544.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215-220. doi: 10.1038/s41586-020-2180-5.
- Abstract Viewed: 547 times
- PDF Downloaded: 365 times